Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP3 | P08254 | 3/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390643 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTFOLH1CTSGCMA1 | |
| SCHEMBL22390659 | 0.89 | LMNA (0.41) | SMN1; SMN2HTTFOLH1LMNAPPARA | |
| SCHEMBL22390662 | 0.89 | LMNA (0.41) | SMN1; SMN2HTTFOLH1LMNAPPARA | |
| SCHEMBL22390782 | 0.86 | FOLH1 (0.46) | SMN1; SMN2HTTFOLH1CYP2C19LMNA | |
| SCHEMBL22390783 | 0.86 | FOLH1 (0.46) | SMN1; SMN2HTTFOLH1CYP2C19LMNA | |
| SCHEMBL22390749 | 0.84 | SLC1A3 (0.41) | SMN1; SMN2HTTFOLH1CTSGCMA1 | |
| SCHEMBL22390748 | 0.84 | SLC1A3 (0.41) | SMN1; SMN2HTTFOLH1CTSGCMA1 | |
| SCHEMBL22404743 | 0.84 | PPARA (0.61) | PPARA | |
| SCHEMBL4291672 | 0.77 | CTSG (0.65) | SMN1; SMN2HTTCTSGCMA1MME | |
| SCHEMBL6942656 | 0.77 | CTSG (0.65) | SMN1; SMN2HTTCTSGCMA1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | SMN1; SMN2 899/4885HTT 2682/4885FOLH1 949/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | SMN1; SMN2 899/4885HTT 2682/4885FOLH1 949/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | SMN1; SMN2 899/4885HTT 2682/4885FOLH1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.